We collected 76 clinical isolates of Acinetobacter baumannii (amikacin MIC by Vitek 2 AST-N055 card: ≤2μg/mL, 11 isolates; 4μg/mL, 19 isolates; 8μg/ mL, 17 isolates; 16μg/mL, 27 isolates; and ≥64μg/ mL, 2 isolates) from a university hospital and evaluated the Vitek 2 AST-N055 card vs the broth microdilution as a reference method for testing susceptibility to amikacin. Vitek 2 AST-N055 card yielded very major errors in 15 isolates (19.7%) and minor errors in 26 isolates (34.2%). Of the 15 isolates shown very major errors, 14 had Vitek 2 MICs ranging from 8 to 16μg/mL. The results of our study suggest strongly that it is unreliable to test the amikacin susceptibility by Vitek 2 AST-N055 card of A. baumannii with the Vitek 2 MICs ranging from 8 to 16μg/mL. In those cases, another susceptibility test, such as broth microdilution (BMD), should be performed to confirm the results. 
Acinetobacter baumannii is an important pathogen that causes various hospital-acquired infections [1] . Multidrug-resistance in A. baumannii has been increasing rapidly worldwide [2] [3] [4] .
The clinical microbiology laboratory of our hospital uses Vitek 2 system for the routine antimicrobial susceptibility testing of A. baumannii isolates. According to the manufacturer's guideline of Vitek 2 AST-N055 card, amikacin susceptibility to A. baumannii may be performed as an alternative method prior to reporting the results. Thus, we evaluated the AST-N055 card of the Vitek 2 system for amikacin susceptibility testing of A. baumannii isolates.
From August 2007 to December 2008, we collected 76 non-duplicate clinical isolates of A. baumannii (amikacin MIC by Vitek 2 AST-N055 card: ≤2μg/mL, 11 isolates; 4μg/mL, 19 isolates; 8μg/mL, 17 isolates; 16μg/mL, 27 isolates; and ≥64μg/mL, 2 isolates) from a hospital. The turbidity of bacterial suspension was adjusted to a 0.6 McFarland standard. The amikacin susceptibility testing of the 76 A. baumannii strains was performed with broth microdilution (BMD) method. The reference MIC was determined by the BMD with cation-adjusted Mueller-Hinton broth according to the Clinical and Laboratory Standards Institute (CLSI) guidelines [5] . Pseudomonas aeruginosa ATCC 27853 and Escherichia coli ATCC 25922 were used as the quality control strains.
Using the BMD as the reference method, Vitek 2 AST-N055 cards showed very major errors in 15 isolates (19.7%) and minor errors in 26 isolates (34.2%). Of the 15 isolates shown very major errors, 14 isolates had the Vitek 2 MICs ranging from 8 to 16μg/ mL. Of the 44 isolates with Vitek 2 MICs of 8∼16μg/mL, 33 isolates (75%) were intermediate (19 isolates) or resistant (14 isolates) ( Table 1) . The two previous studies that compared between amikacin Vitek 2 system and BMD for 31 and 20 A. baumannii isolates, respectively, showed a satisfactory agreement [6, 7] . However, our investigation differed from those of the other researchers in that we used a well-selected collection of challenge strains with known amikacin MIC by Vitek 2 AST-N055 cards instead of using a collection of consecutive isolates from routine clinical specimens. Forty-four of the 76 A. baumannii isolates showed the Vitek 2 MIC ranging from 8 to 16 μg/mL. In our hospital, most of the amikacin-susceptible A. baumannii isolates showed MICs of 2 to 4μg/mL, but the isolates with the MICs of 8 to 16μg/mL were rare (data not shown).
To evaluate inoculum size as a determinant in the difference of the MIC results obtained with the Vitek 2 system, 48 of the 76 A. baumannii isolates were also tested by using a 1.5 McFarland standard inoculum for Vitek 2 system. The categorical results of the amikacin susceptibility were the same as a 0.6 McFarland standard inoculum was used (data not shown).
In conclusions, the results of our study are strongly suggestive of the Vitek 2 AST-N055 card being unreliable in the amikacin susceptibility testing of A. baumannii with Vitek 2 MICs ranging from 8 to 16 μg/mL. So, in those cases, we recommend an additional susceptibility test such as BMD should be performed to confirm the results.
